CJC-1295 No DAC in India

Name: CJC-1295 No DAC
Brand: Prime Peptide
SKU: PR-CD10
Price: 4499.0 INR
Availability: InStock

PRODUCT OVERVIEW

What is CJC-1295 No DAC?

CJC-1295 No DAC, also known as Modified GRF 1-29, is a synthetic analogue of growth hormone-releasing hormone studied in laboratory models involving GHRH-receptor signaling, pituitary responses, pulsatile growth-hormone release, and downstream IGF-1 pathways.

Its shorter-acting profile is commonly used in research designs focused on timing, receptor activation, and comparative peptide signaling.

Purity≥99%

Molecular Weight3,367.9 g/mol

SequenceY-dA-DAIFTNSYRKVLGQLSARKLLQDIMSR-NH2

StorageStore refrigerated at 2–8°C

FormLyophilized powder

Research UseFor in-vitro laboratory research only

Research mechanism Product-specific pathway illustration

RESEARCH AREAS

CJC-1295 No DAC Potential Use Cases

Product-specific research applications associated with Prime Peptide CJC-1295 No DAC.

GHRH-receptor signaling research

Pituitary response models

Pulsatile growth-hormone release studies

IGF-1 pathway research

Peptide timing and half-life comparisons

Endocrine signaling assays

KEY BENEFITS

CJC-1295 No DAC Research Highlights

Key research-oriented characteristics connected to Prime Peptide CJC-1295 No DAC.

Defined Modified GRF 1-29 sequence
Short-acting research profile
Suitable for timing-based study designs
Useful for comparative GHRH analogue research

SPECIFICATIONS

CJC-1295 No DAC Molecular Data

Molecular specifications for Prime Peptide CJC-1295 No DAC
Molecular Formula	C152H252N44O42
Molecular Weight	3,367.9 g/mol
Purity	≥99%
Appearance	White lyophilized powder
Solubility	Water-soluble
Storage	Store refrigerated at 2–8°C
Research Use	For in-vitro laboratory research only

3D Structure · Representative Model

BIOLOGICAL & MOLECULAR TARGETS

CJC-1295 No DAC Research Targets

Growth hormone-releasing hormone receptor

GHRHR

G protein-coupled receptor

A G protein-coupled receptor on pituitary somatotroph cells that mediates growth hormone-releasing hormone signaling and supports endogenous growth hormone secretion.

View reference ↗

SCIENTIFIC SOURCES

CJC-1295 No DAC Citations & References

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

Journal of Clinical Endocrinology & Metabolism 2006

Randomized controlled studies of long-acting, DAC-containing CJC-1295 in healthy adults reported sustained increases in GH and IGF-1. This citation supports the CJC-1295 pathway context but is not direct formulation-specific evidence for CJC-1295 No DAC.

Read publication →

Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog

Journal of Clinical Endocrinology & Metabolism 2006

In healthy men, long-acting DAC-containing CJC-1295 increased mean and trough GH and IGF-1 while preserving GH pulsatility. The formulation distinction must be retained when discussing No DAC material.

Read publication →

Advances in the detection of growth hormone releasing hormone synthetic analogs

Drug Testing and Analysis 2021

Analytical research treated CJC-1295 and CJC-1295 with Drug Affinity Complex as distinguishable GHRH synthetic analog materials, supporting explicit formulation-level terminology.

Read publication →

TERMINOLOGY

CJC-1295 No DAC Glossary

CJC-1295 No DAC — A non-DAC GHRH-analogue designation commonly used for modified GRF(1-29); it should be distinguished from albumin-binding CJC-1295 with DAC.

CJC-1295 No DAC is a marketplace and research-material designation commonly associated with a modified 29-amino-acid growth hormone-releasing hormone fragment. It lacks the Drug Affinity Complex used by long-acting albumin-binding CJC-1295. Consequently, evidence from clinical studies of CJC-1295 with DAC should not be treated as direct formulation-specific evidence for the No DAC material.

Also known as: Modified GRF(1-29), Mod GRF 1-29, CJC-1295 without DAC Source ↗

Modified GRF(1-29) — A modified analogue of the biologically active 1-29 fragment of human growth hormone-releasing factor.

Modified GRF(1-29) refers to an analogue based on the active N-terminal 29-residue portion of human growth hormone-releasing factor. Research on GHRH(1-29) analogues established that this shortened region can retain growth-hormone-releasing activity, while sequence modifications can alter stability and potency.

Also known as: Mod GRF 1-29, modified growth hormone-releasing factor 1-29 Source ↗

Drug Affinity Complex (DAC) — A conjugation strategy used in long-acting CJC-1295 to bind endogenous albumin and extend exposure.

The Drug Affinity Complex in CJC-1295 enables covalent association with circulating albumin, producing prolonged pharmacokinetic exposure. The absence of this component is the defining distinction implied by the term CJC-1295 No DAC.

Also known as: DAC, albumin-binding conjugation Source ↗

Growth hormone pulsatility — The episodic pattern in which growth hormone is secreted in distinct pulses rather than at a constant rate.

Growth hormone pulsatility describes the naturally episodic release of growth hormone. A study of long-acting CJC-1295 with DAC reported increased mean and trough GH while preserving the pulsatile secretion pattern; that result pertains to the DAC formulation.

Source ↗

COMMON RESEARCH QUESTIONS

CJC-1295 No DAC FAQ

What is CJC-1295 No DAC?

CJC-1295 No DAC is a research-material designation commonly associated with modified GRF(1-29), a non-DAC analogue of the active 1-29 region of growth hormone-releasing hormone. It should not be treated as identical to the long-acting albumin-binding CJC-1295 formulation studied in classic human trials.

How does CJC-1295 No DAC differ from CJC-1295 with DAC?

CJC-1295 with DAC contains an albumin-binding Drug Affinity Complex designed to prolong systemic exposure. CJC-1295 No DAC lacks that component and is commonly associated with modified GRF(1-29). The two names therefore describe materially different research preparations.

Which receptor pathway is associated with CJC-1295 No DAC?

As a GHRH analogue, CJC-1295 No DAC is studied in relation to the growth hormone-releasing hormone receptor, or GHRHR, on pituitary somatotroph cells. Activation of this pathway is associated with endogenous growth hormone release and downstream IGF-1 signaling.

What does modified GRF(1-29) mean?

GRF(1-29) identifies the biologically active first 29 amino acids of human growth hormone-releasing factor. The word modified indicates sequence changes intended to alter properties such as resistance to degradation while retaining GHRH-receptor activity.

What evidence supports the CJC-1295 No DAC research summary?

The pathway summary is supported by research on GHRH(1-29) analogues, CJC-1295 receptor biology, analytical differentiation of CJC-1295 materials, and human studies of long-acting CJC-1295 with DAC. Evidence from DAC studies is included for mechanistic context and is clearly labeled rather than presented as direct No DAC clinical evidence.

Do CJC-1295 with DAC studies apply directly to CJC-1295 No DAC?

No. Studies of albumin-binding CJC-1295 with DAC provide useful receptor and GH-axis context, but their pharmacokinetic and clinical findings cannot be transferred directly to a non-DAC preparation. The product research page should preserve this distinction wherever those studies are cited.